Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

To screen or not to screen?

L J Denis1

  • 1Department of Urology, A.Z. Middelheim, Antwerp, Belgium.

The Prostate. Supplement
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Prostate cancer screening faces challenges due to unreliable tests like PSA, DRE, and TRUS. Ongoing pilot studies will determine if screening effectively reduces prostate cancer mortality.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor, nodes, metastasis (TNM) classification of bladder cancer.

Urologic oncology·2011
Same author

The story of the European Randomized Study of Screening for Prostate Cancer.

BJU international·2004
Same author

Branding the ERSPC: a waste or a need?

BJU international·2004
Same author

Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2001
Same author

Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences.

The Prostate·2001
Same author

The role of active treatment in early prostate cancer.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2000
Same journal

Clinical perspective on apoptosis in the management of the BPH patient.

The Prostate. Supplement·2000
Same journal

Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease.

The Prostate. Supplement·2000
Same journal

Effects of alpha1-adrenoceptor antagonists on cultured prostatic smooth muscle cells.

The Prostate. Supplement·2000
Same journal

Alpha(1)-adrenoceptors (alpha(1)-AR) and vascular smooth muscle cell growth.

The Prostate. Supplement·2000
Same journal

Regulation of apoptosis in prostatic disease.

The Prostate. Supplement·2000
Same journal

In vitro models of prostate apoptosis: clusterin as an antiapoptotic mediator.

The Prostate. Supplement·2000
See all related articles

Area of Science:

  • Urology
  • Oncology
  • Preventive Medicine

Background:

  • Recent medical committee decisions question the efficacy of prostate cancer screening.
  • Prostate cancer screening protocols often fail to meet established criteria for effective population-wide programs.

Purpose of the Study:

  • To evaluate the effectiveness of prostate cancer screening methods.
  • To present a case for and against current prostate cancer screening practices.

Main Methods:

  • Review of existing screening tests: digital rectal examination (DRE), prostate-specific antigen (PSA), and transrectal ultrasound (TRUS).
  • Analysis of a pilot study in Antwerp and Rotterdam involving various screening combinations and randomization.
  • The study includes pre-screening with PSA or urinary symptom questionnaires, followed by DRE and TRUS, with PSA measurement for suspicious cases.

Related Experiment Videos

Main Results:

  • Current screening tests (DRE, PSA, TRUS) exhibit variable sensitivities (50%-85%) and a low positive predictive value (around 30%).
  • The pilot study aims to assess if combined testing improves detection rates.

Conclusions:

  • No single test reliably detects prostate cancer; all have limitations.
  • The long-term impact of current screening strategies on prostate cancer mortality remains under investigation, with results from pilot studies expected in approximately 8 years.